期刊文献+

BNIP3基因甲基化与早期结直肠癌患者临床病理特征的关系 被引量:2

Relationship between BNIP3 gene methylation and clinicopathological characteristics in patients with early-stage colorectal cancer
原文传递
导出
摘要 目的分析早期结直肠癌组织中BNIP3基因启动子区CpG岛甲基化与患者临床病理特征的关系,评价其在结直肠癌发生发展中的作用。方法用甲基化特异性PCR技术分析107例早期结直肠癌患者肿瘤组织中BNIP3基因启动子区CpG岛甲基化状态。结果本组结直肠癌组织标本中BNIP3基因启动子区CpG岛甲基化阳性率为58.9%(63/107)。右半结肠组肿瘤组织中BNIP3基因甲基化明显高于左半结肠组(P<0.001);低分化组明显高于高中分化组(P=0.002)。BNIP3基因甲基化在患者性别、年龄、肿瘤大小和分期等分组间无明显差异。结论早期结直肠癌组织中存在BNIP3基因启动子区CpG岛甲基化。BNIP3基因高甲基化与早期结直肠癌部位和分化程度密切相关。 Objectives To detect the DNA methylation status of the CpG island in BNIP3 gene promoter in patients with early-stage colorectal cancer,and to determine its relationship with clinicopathological features and its role in the development and progress of colorectal cancer.Methods Methylation specific PCR,DNA methylation status of the BNIP3 gene was analyzed in 107 patients with early-stage colorectal cancer.Results Hypermethylation of the CpG island in BNIP3 gene promoter was detected in 63 patients(63/107,58.9%).The aberrant methylation of the BNIP3 gene was more common in the right colon cancer group than in the left colon cancer group(P0.001).The BNIP3 methylation status was higher in the poor differentiated group than in the well and mediate differented group(P=0.002).There was no association between BNIP3 gene methylation and gender,age,tumor size,or stage.Conclusions There was aberrant methylation of the BNIP3 gene in early-stage colorectal cancers.Hypermethylation of the CpG island in BNIP3 gene promoter correlates with both tumor location and differentiation status in patients with early-stage colorectal cancer.
出处 《中华普外科手术学杂志(电子版)》 2012年第4期51-53,共3页 Chinese Journal of Operative Procedures of General Surgery(Electronic Edition)
基金 国家自然科学基金资助项目(81000898)
关键词 结直肠肿瘤 DNA甲基化 BNIP3基因 Colorectal neoplasms DNA methylation BNIP3 gene
  • 相关文献

二级参考文献47

  • 1Modrich P, Lahue R. Mismatch repair in replication fidelity, genetic recombination, and cancer biology. Annu Rev Biothem 1996; 65:101-133.
  • 2Stojic L, Brun R, Jiricny J. Mismatch repair and DNA damage signalling. DATA Repair (Amst) 2004; 3:1091-1101.
  • 3Fink D, Aebi S, Howell SB. The role of DNA mismatch repair in drug resistance. Clin Cancer Res 1998; 4:1-6.
  • 4Zeng X, Yan T, Schupp JE, Seo Y, Kinsella TJ. DNA mismatch repair initiates 6-thioguanine-induced autophagy through p53 activation in human tumor cells. Clin Cancer Res 2007; 13:1315-1321.
  • 5Zeng X, Kinsella TJ. A novel role for DNA mismatch repair and the autophagic processing of chemotherapy drugs in human tumor cells. Autophagy 2007; 3:368-370.
  • 6Elion GB. The purine path to chemotherapy. Science 1989; 244:41-47.
  • 7Swarm PF, Waters TR, Moulton DC, et al. Role of postreplicative DNA mismatch repair in the cytotoxic action of thioguanine. Science 1996; 273:1109-1111.
  • 8Yan T, Berry SE, Desai AB, Kinsella TJ. DNA mismatch repair (MMR) mediates 6-thioguanine genotoxicity by introducing single-strand breaks to signal a G2-M arrest in MMR- proficient RKO cells. Clin Cancer Res 2003; 9:2327-2334.
  • 9Seglen PO, Bohley E Autophagy and other vacuolar protein degradation mechanisms. Experientia 1992; 48:158-172.
  • 10Dunn WA, Jr. Studies on the mechanisms of autophagy: maturation of the autophagic vacuole. J Cell Biol 1990; 110:1935- 1945.

共引文献3

同被引文献15

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部